September brought new options for breast, lung, kidney, bile duct, skin and neuroendocrine cancers, plus a brain tumor scan and easier lung cancer treatment.
|Articles|January 6, 2021
The Top 5 Skin Cancer News and Updates That Patients May Have Missed in 2020
Author(s)CURE staff
Listen
0:00 / 0:00
Key Takeaways
- Circulating tumor cells in stage 3 melanoma patients serve as a biomarker for relapse, aiding treatment strategies.
- Tafinlar and Mekinist achieved over 50% relapse-free survival in BRAF V600E/K-mutant melanoma, per COMBI-AD trial results.
A roundup of some skin cancer news and updates that occurred in 2020 that patients may have missed.
Advertisement
There were several updates in the field of skin cancer in 2020. Here, CURE® looks back at some of the most-read news and updates in the field of skin cancer that patients may have missed.
- Patients with stage 3 melanoma who had one or more circulating tumor cells were found to relapse sooner, providing physicians with an important biomarker to treat the likelihood of relapse.
READ MORE .
- Adjuvant Tafinlar (dabrafenib) and Mekinist (trametinib) elicited a greater than 50% relapse-free survival (RFS) rate in patients with resected, stage 3 BRAF V600E/K-mutant melanoma, according to findings from a five-year analysis of the phase 3 COMBI-AD trial.
READ MORE . - A personalized vaccine has demonstrated long-term disease-free and overall survival benefits in patients with stage 3 or stage 4 melanoma at a high risk of recurrence following complete surgical resection, according to the vaccine’s manufacturer, Elios Therapeutics.
READ MORE . - Patients appear open to the idea of using artificial intelligence (AI) to help in screening for skin cancer, however many patients stress the need to preserve the patient-physician relationship if implemented, according to study results published in JAMA Dermatology.
READ MORE . - Following a median follow-up of three years, the use of immunotherapy agent Keytruda (pembrolizumab) for the adjuvant treatment of patients with resected, high-risk, stage 3 melanoma demonstrated a sustained and clinical meaningful improvement in recurrence-free survival (RFS), compared with placebo.
READ MORE .
For more news on cancer updates, research and education, don’t forget to
Advertisement
Related to this article
Relatives of people with BRCA1 or BRCA2 variants completed genetic testing more often when a navigator reached out directly than when they received a letter.
The FDA approval is based on the phase 3 BRUIN CLL-313 trial, in which 94% of patients responded to Jaypirca compared with 81% who received chemoimmunotherapy.
Giredestrant plus Afinitor lowered the risk of cancer worsening or death by 62% in patients with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer.
Five-year results presented at ASTRO 2026 show a five-week radiation schedule after prostatectomy controls cancer as well as a seven-week course. But serious urinary side effects were more common.
A study of more than 17,000 patients ages 23 to 64, presented at ASTRO 2026, found that only about 28% took endocrine therapy consistently for five years, and people who skipped radiation were more likely to fall off. Here's what to weigh before making that choice.
Dr. Nitin Ohri explains how radiation treats cancer, how often treatment is needed, common side effects and how to tell if radiation is working.
Ivonescimab outperformed Keytruda, a new myeloma drug lowered progression risk by 60% and more: the biggest phase 3 cancer results of September 2026.
Advertisement
Advertisement
Trending on CURE
1
Hot Flashes From Breast Cancer Treatment May Soon Have an FDA-Approved Fix
2
The 5 Most Impactful Phase 3 Cancer Trial Results From September 2026
3
10 Cancer Treatment Approvals From September 2026 and What They Mean for You
4
Shorter Radiation After Prostate Surgery Controlled Cancer as Well at 5 Years, With a Trade-Off
5